Peptides and Peptidomimetics As Therapeutic Agents for Covid-19

Overview

Journal Pept Sci (Hoboken)

Date 2021 Dec 13

PMID 34901700

Citations 8

Authors

Achyut Dahal

Jafrin Jobayer Sonju

Konstantin G Kousoulas

Seetharama D Jois

Affiliations

Soon will be listed here.

Abstract

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Covid-19 pandemic has caused high morbidity and mortality rates worldwide. Virus entry into cells can be blocked using several strategies, including inhibition of protein-protein interactions (PPIs) between the viral spike glycoprotein and cellular receptors, as well as blocking of spike protein conformational changes that are required for cleavage/activation and fusogenicity. The spike-mediated viral attachment and entry into cells via fusion of the viral envelope with cellular membranes involve PPIs mediated by short peptide fragments exhibiting particular secondary structures. Thus, peptides that can inhibit these PPIs may be used as potential antiviral agents preventing virus entry and spread. This review is focused on peptides and peptidomimetics as PPI modulators and protease inhibitors against SARS-CoV-2.

Citing Articles

Peptide Inhibitor Assay for Allocating Functionally Important Accessible Sites Throughout a Protein Chain: Restriction Endonuclease EcoRI as a Model Protein System.

Otaki J BioTech (Basel). 2025; 14(1.

PMID: 39846550 PMC: 11755562. DOI: 10.3390/biotech14010001.

Peptide-Based Inhibitors of Protein-Protein Interactions (PPIs): A Case Study on the Interaction Between SARS-CoV-2 Spike Protein and Human Angiotensin-Converting Enzyme 2 (hACE2).

Rakhmetullina A, Zielenkiewicz P, Odolczyk N Biomedicines. 2024; 12(10).

PMID: 39457672 PMC: 11504900. DOI: 10.3390/biomedicines12102361.

A Multi-Faceted Binding Assessment of Aptamers Targeting the SARS-CoV-2 Spike Protein.

Civit L, Moradzadeh N, Jonczyk A, Neckermann P, Asbach B, Peterhoff D Int J Mol Sci. 2024; 25(9).

PMID: 38731860 PMC: 11083479. DOI: 10.3390/ijms25094642.

A Comprehensive Technology Platform for the Rapid Discovery of Peptide Inhibitors against SARS-CoV-2 Pseudovirus Infection.

Beeg M, Baroni S, Piotti A, Porta A, De Luigi A, Cagnotto A Int J Mol Sci. 2023; 24(15).

PMID: 37569522 PMC: 10418426. DOI: 10.3390/ijms241512146.

A lysine-based 2:1-[α/aza]-pseudopeptide series used as additives in polymeric membranes for CO capture: synthesis, structural studies, and application.

Ibrahim M, Solimando X, Stefan L, Pickaert G, Babin J, Arnal-Herault C RSC Adv. 2023; 13(15):10051-10067.

PMID: 37006376 PMC: 10052764. DOI: 10.1039/d3ra00409k.

References

Korber B, Fischer W, Gnanakaran S, Yoon H, Theiler J, Abfalterer W . Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020; 182(4):812-827.e19. PMC: 7332439. DOI: 10.1016/j.cell.2020.06.043. View

Eliasen R, Daly N, Wulff B, Andresen T, Conde-Frieboes K, Craik D . Design, synthesis, structural and functional characterization of novel melanocortin agonists based on the cyclotide kalata B1. J Biol Chem. 2012; 287(48):40493-501. PMC: 3504764. DOI: 10.1074/jbc.M112.395442. View

London N, Raveh B, Schueler-Furman O . Druggable protein-protein interactions--from hot spots to hot segments. Curr Opin Chem Biol. 2013; 17(6):952-9. DOI: 10.1016/j.cbpa.2013.10.011. View

Kim J, Jang J, Kim J, Chung Y, Yoo C, Han M . Genome-Wide Identification and Characterization of Point Mutations in the SARS-CoV-2 Genome. Osong Public Health Res Perspect. 2020; 11(3):101-111. PMC: 7282418. DOI: 10.24171/j.phrp.2020.11.3.05. View

Ke Z, Oton J, Qu K, Cortese M, Zila V, McKeane L . Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature. 2020; 588(7838):498-502. PMC: 7116492. DOI: 10.1038/s41586-020-2665-2. View

Padhi A, Tripathi T . Can SARS-CoV-2 Accumulate Mutations in the S-Protein to Increase Pathogenicity?. ACS Pharmacol Transl Sci. 2020; 3(5):1023-1026. PMC: 7551720. DOI: 10.1021/acsptsci.0c00113. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Zhu Y, Yu D, Yan H, Chong H, He Y . Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. J Virol. 2020; 94(14). PMC: 7343218. DOI: 10.1128/JVI.00635-20. View

10.

Alam I, Radovanovic A, Incitti R, Kamau A, Alarawi M, Azhar E . CovMT: an interactive SARS-CoV-2 mutation tracker, with a focus on critical variants. Lancet Infect Dis. 2021; 21(5):602. PMC: 7906688. DOI: 10.1016/S1473-3099(21)00078-5. View

11.

Morgan D, Morris C, Mahindra A, Blair C, Tejeda G, Herbert I . Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalization. Pept Sci (Hoboken). 2021; 113(4):e24217. PMC: 7883042. DOI: 10.1002/pep2.24217. View

12.

Laxio Arenas J, Kaffy J, Ongeri S . Peptides and peptidomimetics as inhibitors of protein-protein interactions involving β-sheet secondary structures. Curr Opin Chem Biol. 2019; 52:157-167. DOI: 10.1016/j.cbpa.2019.07.008. View

13.

Zhao L, Chmielewski J . Inhibiting protein-protein interactions using designed molecules. Curr Opin Struct Biol. 2005; 15(1):31-4. DOI: 10.1016/j.sbi.2005.01.005. View

14.

Zhang L, Jackson C, Mou H, Ojha A, Peng H, Quinlan B . SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020; 11(1):6013. PMC: 7693302. DOI: 10.1038/s41467-020-19808-4. View

15.

Sanche S, Lin Y, Xu C, Romero-Severson E, Hengartner N, Ke R . High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2020; 26(7):1470-1477. PMC: 7323562. DOI: 10.3201/eid2607.200282. View

16.

Maas M, Hintzen J, Loffler P, Mecinovic J . Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides. Chem Commun (Camb). 2021; 57(26):3283-3286. DOI: 10.1039/d0cc08387a. View

17.

Adhikary P, Kandel S, Mamani U, Mustafa B, Hao S, Qiu J . Discovery of Small Anti-ACE2 Peptides to Inhibit SARS-CoV-2 Infectivity. Adv Ther (Weinh). 2021; 4(7):2100087. PMC: 8212088. DOI: 10.1002/adtp.202100087. View

18.

Wang G, Yang M, Duan Z, Liu F, Jin L, Long C . Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models. Cell Res. 2020; 31(1):17-24. PMC: 7705431. DOI: 10.1038/s41422-020-00450-0. View

19.

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S . Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020; 30(4):343-355. PMC: 7104723. DOI: 10.1038/s41422-020-0305-x. View

20.

Alai S, Gujar N, Joshi M, Gautam M, Gairola S . Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein. Heliyon. 2021; 7(3):e06564. PMC: 7972664. DOI: 10.1016/j.heliyon.2021.e06564. View